Anastrazolos 1 mg Pharmacom Labs

Description

Anastrazolos 1 mg Pharmacom Labs — anastrozole from Pharmacom Labs at 1 mg. Reversible aromatase inhibitor with 46-hour half-life. Primary on-cycle estrogen control compound; dose-titrate by E2 bloodwork.

Key Benefits

• Aromatase inhibitor — blocks oestrogen synthesis at the source
• Standard on-cycle AI for testosterone-based protocols
• Low dose (0.25–0.5 mg EOD) typically sufficient for 400–500 mg test
• Dose by bloodwork — sensitive E2 assay, target 20–40 pg/mL
• Crashing E2 feels worse than mildly elevated E2 — err on the low side
• Each unit dosed at 1 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 0.25–0.5 mg every other day on testosterone-based cycles. Titrate to bloodwork (sensitive E2 assay, target 20–40 pg/mL). Higher doses required only on aggressive 700+ mg/week test protocols. During PCT: not used (blocks oestrogen needed for LH signalling).

How It Works

Non-steroidal aromatase inhibitor. Binds and inactivates the aromatase enzyme (CYP19A1) that converts testosterone and androstenedione to estradiol and estrone. Reversible binding — effect disappears within days of stopping.

Pharmacokinetics

Plasma half-life approximately 50 hours. Every-other-day dosing produces stable serum and tissue levels. Steady-state in 7 days.

Potential Side Effects

Primary risk: crashed E2 — joint pain, low libido, lethargy, brain fog. If these appear, drop dose immediately. Lipid impact modest. No hepatic toxicity.

Cycle & Stacking Guide

Used on-cycle with aromatising compounds (testosterone, methandienone, oxymetholone). Start at 0.25 mg EOD, bloodwork at week 4, adjust. Never used during PCT — needed estrogen signalling for LH/FSH recovery.

Manufacturer Notes

Pharmacom Labs operates from EU-registered facilities with in-house HPLC verification. Every batch ships with a unique code on the label — scannable at pharmacom-labs.com to confirm authenticity before the vial ever leaves the box.

Storage & Handling

Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.